Latest Ratios: P/E Ratio 0.0x · EV/EBITDA N/A · ROE 80.6%. (2021–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Market Cap | $20588 | — | $26353 | — | — | — |
| Enterprise Value | $4M | — | $3M | — | — | — |
| P/E Ratio → | 0.00 | — | — | — | — | — |
| P/S Ratio | 0.00 | — | 0.00 | — | — | — |
| P/B Ratio | 0.00 | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | — | 0.48 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Gross Margin | 20.2% | 20.2% | 33.6% | 32.7% | 25.9% | 24.9% |
| Operating Margin | -226.9% | -226.9% | -21.4% | 0.8% | -8.5% | 4.8% |
| Net Profit Margin | 209.0% | 209.0% | -9.7% | 2.5% | 7.7% | -0.0% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| ROE | 80.6% | 80.6% | -59.5% | 7.8% | 455.6% | — |
| ROA | 54.4% | 54.4% | -13.0% | 3.5% | 21.2% | -0.0% |
| ROIC | -51.6% | -51.6% | -37.7% | 1.6% | -149.2% | — |
| ROCE | -68.7% | -68.7% | -55.0% | 2.3% | -144.5% | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Debt / Equity | 0.19 | 0.19 | — | 0.10 | 4.49 | — |
| Debt / EBITDA | — | — | — | 1.22 | — | 1.71 |
| Net Debt / Equity | — | 0.16 | — | 0.09 | 4.22 | — |
| Net Debt / EBITDA | — | — | — | 1.02 | — | 1.66 |
| Debt / FCF | — | — | — | — | — | 0.63 |
| Interest Coverage | 16.78 | 16.78 | -0.23 | 3.35 | 5.42 | 2.77 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 3.12 | 3.12 | 1.17 | 2.19 | 0.94 | 0.40 |
| Quick Ratio | 2.98 | 2.98 | 1.14 | 2.08 | 0.92 | 0.38 |
| Cash Ratio | 0.32 | 0.32 | 0.17 | 0.05 | 0.01 | 0.01 |
| Asset Turnover | — | 0.14 | 1.52 | 1.14 | 2.05 | 2.91 |
| Inventory Turnover | 11.24 | 11.24 | 44.62 | 27.36 | 93.92 | 74.94 |
| Days Sales Outstanding | — | 82.56 | 158.72 | 36.92 | 142.72 | 66.51 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Earnings Yield | 100.0% | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | — | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | — | 0.0% | — | — | — |
| Shares Outstanding | — | $588235 | $588235 | $262190 | $262190 | $262190 |
Imminent liquidity insolvency risk
As reported in recent financial statements, the company's operating margin of -85.5% in 2024Q4 underscores a profound inability to cover fixed clinical overhead, a trend that appears to have worsened significantly compared to the more stable, albeit still negative, historical performance observed in previous fiscal periods.
The wide gap between gross margins and operating margins suggests that the company's administrative and corporate costs are disproportionately high relative to its current patient throughput. Investors should monitor whether the company can achieve any meaningful scale, as the current cost structure appears fundamentally misaligned with its revenue-generating capacity.
Based on the latest quarterly data, the company's ROIC of -33.9% reflects a severe destruction of invested capital, a sharp deterioration from the -4.8% reported in 2023Q4, indicating that the firm is failing to generate adequate returns on its clinical and operational investments.
This negative trajectory in return on capital suggests that the company's expansion into new jurisdictions has not yet yielded the necessary efficiencies to offset the high costs of medical labor and facility maintenance. The persistent decay in these metrics warrants investigation into whether the current business model is capable of ever reaching a break-even point.
According to recent filings, the company's cash conversion cycle of -45 days in 2024Q4, while appearing efficient, likely masks significant liquidity pressures, as the firm struggles to balance its long-term surrogacy service obligations against the rapid depletion of its available cash reserves and rising accounts payable.
The high days sales outstanding of 270 days suggests that the company is facing significant delays in collecting payments from its international patient base, which is a critical risk for a business with such limited liquidity. This inefficiency in cash collection forces the company to rely on external financing to maintain its daily operations.
As indicated by the 2024Q4 current ratio of 1.17, the company's liquidity position has become increasingly precarious, with cash reserves dwindling to levels that may be insufficient to cover near-term liabilities, as reported in the most recent quarterly financial disclosures provided by the firm.
The reliance on a narrow liquidity buffer leaves the company highly vulnerable to any unexpected operational disruptions or regulatory shifts in its key markets. Without a significant infusion of capital or a drastic reduction in cash burn, the company may face an imminent liquidity crisis that could threaten its ongoing viability.
Financial disclosures reveal that the company's net margin of 209.02% is a misleading indicator of operational health, as it is heavily distorted by non-operating gains, likely from warrant liability adjustments, which obscure the underlying reality of the company's persistent and significant clinical operating losses.
Analysts frequently misapply net income-based ratios to this business model, failing to strip out these non-cash accounting artifacts. Investors should instead focus on operating cash flow and gross margin trends to gain a more accurate understanding of the company's true earning power and its ability to sustain operations.
Includes 30+ ratios · 5 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NIVFW stock.
NewGenIvf Group Limited's current P/E ratio is 0.0x. This places it at the 50th percentile of its historical range.
NewGenIvf Group Limited's return on equity (ROE) is 80.6%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 121.1%.
Based on historical data, NewGenIvf Group Limited is trading at a P/E of 0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
NewGenIvf Group Limited has 20.2% gross margin and -226.9% operating margin.